Baker Bros. Advisors’s Ovid Therapeutics OVID Stock Holding History

Baker Bros. Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-955,690	Closed	-$2.21M	–	130
2020 Q4	$2.21M	Buy	955,690 +364,929	+62%	+$1.7M	0.01%	109
2020 Q3	$3.39M	Buy	590,761 +132,508	+29%	+$887K	0.01%	89
2020 Q2	$3.38M	Buy	458,253 +388,782	+560%	+$1.82M	0.01%	85
2020 Q1	$207K	Buy	+69,471	New	+$234K	﹤0.01%	109
2018 Q4	–	Sell	-222,139	Closed	-$1.26M	–	95
2018 Q3	$1.26M	Sell	222,139 -25,594	-10%	-$194K	0.01%	90
2018 Q2	$1.93M	Hold	247,733	–	–	0.01%	95
2018 Q1	$1.75M	Sell	247,733 -85,600	-26%	-$693K	0.01%	93
2017 Q4	$3.29M	Hold	333,333	–	–	0.03%	87
2017 Q3	$2.86M	Hold	333,333	–	–	0.02%	89
2017 Q2	$3.5M	Buy	+333,333	New	+$4.35M	0.03%	72

Other funds holding OVID

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baker Bros. Advisors's OVID Position: Q1 2021 in Review

Baker Bros. Advisors sold out of Ovid Therapeutics (OVID) in Q1 2021, closing a stake of 955,690 shares — an estimated $2.21M sold.

Baker Bros. Advisors first reported a position in OVID in Q2 2017 and held it in 10 quarters. The position peaked at $3.5M in Q2 2017. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

Baker Bros. Advisors reported no remaining Ovid Therapeutics position as of Q1 2021 after selling out during the quarter.
Baker Bros. Advisors sold 955,690 Ovid Therapeutics shares in Q1 2021, an estimated $2.21M.
Baker Bros. Advisors first reported a position in Ovid Therapeutics in Q2 2017 and held it in 10 quarters.
Baker Bros. Advisors's Ovid Therapeutics position peaked at $3.5M in Q2 2017.
88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.